Administration of the ERK kinase inhibitor (PD98059) significantly reduced NOX4 protein expression and collagen production, which indicated that PRR increases collagen production primarily through the PRR-ERK1/2-NOX4 pathway in CFs. Here, MAPK3 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.